CAZZANIGA GIOVANNI
Pubblicazioni
Elli, E., Mauri, M., D’Aliberti, D., Crespiatico, I., Fontana, D., Redaelli, S., et al. (2024). Idiopathic erythrocytosis: a germline disease?. CLINICAL AND EXPERIMENTAL MEDICINE, 24(1) [10.1007/s10238-023-01283-y]. Dettaglio
Crespiatico, I., Zaghi, M., Mastini, C., D'Aliberti, D., Mauri, M., Mercado, C., et al. (2024). First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis. BLOOD [10.1182/blood.2023021349]. Dettaglio
Oikonomou, A., Valsecchi, L., Quadri, M., Watrin, T., Scharov, K., Procopio, S., et al. (2023). High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia. BIOCHEMICAL PHARMACOLOGY, 217(November 2023) [10.1016/j.bcp.2023.115809]. Dettaglio
Palmi, C., Bresolin, S., Junk, S., Fazio, G., Silvestri, D., Zaliova, M., et al. (2023). Definition and Prognostic Value of Ph-like and IKZF1plus Status in Children With Down Syndrome and B-cell Precursor Acute Lymphoblastic Leukemia. HEMASPHERE, 7(6) [10.1097/HS9.0000000000000892]. Dettaglio
Saettini, F., Guerra, F., Fazio, G., Bugarin, C., Mcmillan, H., Ohtake, A., et al. (2023). Correction to: Antibody Deficiency in Patients with Biallelic KARS1 Mutations (Journal of Clinical Immunology, (2023), 43, 8, (2115-2125), 10.1007/s10875-023-01584-7) [Altro] [10.1007/s10875-023-01600-w]. Dettaglio